Search the database for deliberate release of GM medicinal products

Displaying 1 - 2 of 2
EU record number Title Company / Sponsor Treated organism Genetic modification
B/BE/26/BVW2 An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE) AAVantgarde Bio UK Ltd. Humans Non-replicating recombinant dual vector derived from adeno-associated virus AAV8 carrying functional copies of the ABCA4 gene.
B/BE/25/BVW3 Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B CSL Behring LLC Humans Recombinant adeno associated viral vector containing the codon-optimised human PADUA factor IX (FIX) gene

© Sciensano - Version 1.0 (20260902.1)